相关实验视频

Updated: May 10, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

塔拉塔马布-德尔:为患有扩散期小细胞肺癌的患者提供了新的希望

Parveen Kumar Goyal¹, Kavita Sangwan²

¹Department of Pharmacy, Panipat Institute of Engineering &Technology (PIET) Samalkha, Panipat, Haryana, 132102, India.

Current treatment options in oncology

|October 11, 2024

概括

美国FDA于2024年5月批准Tarlatamab-dlle用于扩散阶段小细胞肺癌 (SCLC). 这种新疗法针对DLL3,为这种侵袭性神经内分泌癌症患者提供了希望.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
药理学药理学是指药理学的学科.

背景情况:

小细胞肺癌 (SCLC) 是一种具有侵略性的神经内分泌癌,预后不佳,特别是在广泛的阶段.
治疗选择有限,存活率低,凸显了在广泛阶段的SCLC中需要新型疗法.
美国食品和药物管理局于2024年5月批准了Tarlatamab-dlle,这是一个重大进展.

研究的目的:

审查Tarlatamab-dlle用于广泛阶段SCLC的临床,临床前和药理学方面.
为提供Tarlatamab-dlle作为DLL3向双特异性T细胞参与者的作用机制的概述.
讨论Tarlatamab-dlle用于SCLC治疗的加速批准的影响.

主要方法:

对Tarlatamab-dlle临床试验数据和临床前研究的审查.
分析Tarlatamab-dlle的药理特征,包括其双特异性T细胞参与机制.
审查有关USFDA批准程序的监管信息.

主要成果:

塔拉塔马布-dlle是一种DLL3向的双特异性T细胞吸引剂,已被批准用于广泛阶段的SCLC.
该药物适用于接受基化疗或经历了进展的成年患者.
这项批准为患者群体提供了新的治疗选择,这些患者群体历来表现不佳.

结论:

塔拉塔马布-德尔代表了对广泛阶段的SCLC有前途的新疗法.
进一步的研究和长期数据至关重要,以充分了解其疗效和安全性.
药物的向方法可以改善SCLC患者的生存率和疾病控制.

关键词:

双特异性T细胞参与者.DLL3 - 针对性的目标扩展阶段的扩展阶段小细胞肺癌 (SCLC) 是一种癌症.塔尔拉塔马巴布-德尔 (英语:Tarlatamab-dlle) 是一个古老的小镇.

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...